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Translational relevance
High-risk HPV (hrHPV) DNA testing is now considered an attractive primary cervical cancer screening tool yielding a superior protection against cervical (pre)cancer compared to cytology. However, its relatively low specificity for high-grade cervical (pre)malignant lesions requires secondary, triage testing to distinguish those hrHPV positive women with clinically relevant cervical disease in need of colposcopic examination. This asks for a triage biomarker assay that is easily applicable to physician-taken cervical scrapings as well as self-collected (cervico-)vaginal specimens. The objective triage assay developed and validated in this study (methylation analysis of CADM1 and MAL genes) allows a completely objective, non-morphological molecular-based test system ( i.e. hrHPV followed by molecular triage testing with a CADM1/MAL methylation marker panel) for cervical screening.
Introduction
Recent randomized-controlled cervical cancer screening trials have shown that high-risk human papillomavirus (hrHPV) testing yields a superior protection against cervical precancerous lesions and cervical cancer compared to cytology (1) (2) (3) (4) (5) (6) (7) . Therefore, hrHPV testing is a more attractive primary cervical screening tool than cytology (2, 8) . Moreover, in combination with self-sampling hrHPV testing has shown to improve screening attendance in developed countries (9, 10) and to increase access to cervical screening in low/intermediate resource settings (7, 11, 12) . A drawback of hrHPV testing is the lower specificity (approximately 4-6%) for CIN3 or cervical cancer (CIN3+) compared to cytology. Introduction of a less specific screening test may lead to a substantial increase in the burden of health care resources, particularly in countries that currently have relatively low colposcopy referral rates. To control the number of colposcopy referrals, hrHPV positive women should not be offered colposcopy immediately but should be further stratified by means of secondary (i.e.
triage) tests to guide referral for colposcopy and minimize over-diagnosis and -treatment (3, 13, 14) .
At present cytology is considered an appropriate triage tool for hrHPV-positive women (13) . Immunostaining of cytology slides for p16 INK4a with or without Ki-67 staining potentially yields better results than cytology (15, 16) . However, given their subjective nature, cytologybased methods are not fully compatible with the advantages of hrHPV testing in terms of reproducibility, quality (17, 18) , and sample flexibility, the latter hampering their performance on self-collected cervico-vaginal samples (19) . In order to reach a higher sensitivity of triage testing for hrHPV positive women, cytology may be complemented with genotyping for HPV16 and -18 (HPV16/18) to cover the excess risk of cytomorphologically normal women who harbour one or both of these types (20) (21) (22) triage method with an objective readout should be available that might be applicable to selfsampled specimens as well.
It is well known that following a hrHPV infection specific (epi)genetic alterations of host cell genes are compulsory extra hits for the development of cervical (pre)cancer.
Recently, we identified the CADM1 (cell adhesion molecule 1) gene, originally referred to as TSLC1 (tumor suppressor in lung cancer-1), and MAL (T-lymphocyte maturation associated protein) as novel tumor suppressor genes functionally involved in cervical carcinogenesis (24) (25) (26) . Promoter methylation showed to be the main mode of inactivation of these genes (25, 26) . Subsequent studies using quantitative methylation-specific PCR (qMSP) analysis on tissue specimens revealed that the application of two qMSP assays, representing CADM1 and MAL each, was sufficient to reach the highest positivity rates for CIN3 lesions (97%) and carcinomas (99%), when scoring the sum of these assays * . Hence, when applicable to cervical scrapes a combination of these methylation markers could represent a promising candidate triage tool for hrHPV-positive women.
In this study, we evaluated the potential of assessing promoter methylation of these two genes as an objective triage tool for hrHPV positive women in case of cervical screening by primary hrHPV testing. We composed, trained and validated a CADM1-and MAL-based qMSP marker panel to stratify hrHPV-positive women for CIN3+. Training and validation of the markers were performed on two large, independent sets of hrHPV-positive scrapes that were collected during population-based cervical screenings studies.
Material and Methods

Study populations
For the training set we selected baseline cervical scrapings of 300 of a total of 1,102 hrHPVpositive women participating in the intervention arm of the population-based, randomizedcontrolled screening trial POBASCAM (2, 27) . The training set was used to build a prediction model that enables distinguishing precancer cases from controls. Specifically, we selected 60 women with a histologically-confirmed CIN3+ lesion detected within the first screening round and 240 women without evidence of CIN2 lesions or worse (CIN2+) after two screening rounds (≥5 years of follow-up). Since CIN2 is a poor proxy of precancer and often represents a misclassified CIN1 or CIN3 we on purpose did not include CIN2 cases in the model building phase. In the intervention arm of the POBASCAM trial, the referral policy at the baseline and subsequent screening round was based on a combination of hrHPV Informed consent was obtained from all study participants and this study followed the local ethical guidelines of the medical center.
DNA extraction, bisulfite treatment and quantitative methylation-specific PCR
DNA was isolated from cervical scrapes using NucleoSpin 96 Tissue kit (Macherey-Nagel, Germany) and a Microlab Star robotic system (Hamilton, Germany) according to manufacturers' instructions. Extracted DNA was subjected to bisulfite treatment using the EZ DNA Methylation Kit (Zymo Research, USA) as described previously (25, 26) . Primers, probes, and reaction conditions for qMSP on an ABI 7500 real-time PCR system (Applied Biosystems, USA) to detect promoter hypermethylation of two regions (m12 and m18) in the CADM1 and two regions (m1 and m2) in the MAL promoter were done as described previously (25, 33) . In addition, a PCR for the bisulfite converted housekeeping gene β-actin was performed as a reference. All qMSP assays were run in separate reactions. Cycle 
Statistical analyses
The training cohort was used to compose a panel out of four qMSPs markers (CADM1-m12, CADM1-m18, MAL-m1, MAL-m2). The panel to be selected should best discriminate women with CIN3+ from other hrHPV-positive women. To that end, we considered panels of 1, 2, 3 and 4 markers (in total 15 marker panels). Methylation outcomes were dichotomized (positive/negative) using Ct ratios. The outcome was considered positive if at least one of the markers in a panel had a Ct ratio above its threshold. The thresholds were estimated by maximizing the CIN3+ sensitivity at a given, predefined specificity. The CIN3+ sensitivity maximization was determined at specificity levels of ≥20%, ≥30%, ≥40%, ≥50%, ≥60%, ≥70%, and ≥80%, which yielded for each marker panel a receiver-operating (ROC) curve. To compare the performance of the different marker panels, we carried out 10-fold crossvalidation and measured the performance of each marker panel by the partial cross-validated area under the ROC (AUC). In case two panels had similar partial cross-validated AUC, the panel with the fewest markers was selected. Regarding the calculations, we first computed cross-validated CIN3+ sensitivities at predefined specificity levels and used those values to construct the cross-validated ROC and to compute the partial cross-validated AUC.
In the validation cohort qMSP testing was performed blinded to clinical data using the Ct ratios as thresholds that were estimated in the training set. ROC curves (end-points 
CIN3+ and CIN2+) were computed for the selected marker panel (that is, the marker panel with the highest cross-validated partial AUC in the training data). The ROC curve was compared to the CIN3+ and CIN2+ sensitivities and specificities of cytology and of cytology combined with HPV16/18 genotyping (i.e. presence of HPV16 and/or 18). The threshold used for cytology positivity was borderline dyskaryosis (i.e. ASCUS).
In subsequent logistic regression analyses, the association between age and methylation was studied. The maximization of the CIN3+ sensitivity and the calculation of the cross-validated AUC were performed in the R package (version 2.8. 
Results
Training set analysis
We considered panels of one to four markers (in total 15 marker panels) out of four qMSPs markers (CADM1-m12, CADM1-m18, MAL-m1, MAL-m2) to discriminate amongst 275 hrHPV-positive women those with CIN3+. The composition of training set cohort, which included 51 women with CIN3+ and 224 women without evidence of CIN2+, is outlined in Supplementary Figure 1 . For each panel a cross-validated ROC curve was constructed by optimizing CIN3+ sensitivity at predefined specificity levels of ≥20%, ≥30%, ≥40%, ≥50%, ≥60%, ≥70%, and ≥80%. The cross-validated ROC curve and corresponding partial crossvalidated AUC of the marker panels are shown in Figure 1 . In Supplementary Figure 3 an example of the prediction values of the sensitivity and specificity from the 10-fold cross validation is presented for one of the marker panels (i.e. CADM1-m18/MAL-m1). Roughly, two clusters of ROC curves were found, with cluster 1 comprising a total of seven marker combinations with partial AUC values of over 0.68 (Figure 1) . One of these combinations contained all four markers (CADM1-m12, CADM1-m18, MAL-m1, and MAL-m2), three contained three markers (CADM1-m12, CADM1-m18 and MAL-m1; CADM1-m12, CADM1-m18 and MAL-m2; CADM1-m18, MAL-m1 and MAL-m2), and three contained two markers (CADM1-m12 and CADM1-m18; CADM1-m18 and MAL-m1; CADM1-m18 and MAL-m2).
CADM1-m18 was present in all seven marker combination of cluster 1. Of the panels containing only two markers the combination CADM1-m18 and MAL-m1 had the highest partial AUC (i.e. 0.719; Figure 1 ). Since adding additional qMSP markers did not yield markedly higher AUC values we selected the CADM1-m18/MAL-m1 panel for further evaluation of its clinical performance in the independent validation set.
Validation set analysis
In the validation cohort qMSP testing was performed blinded to clinical data. ROC curves (end-points CIN3+ and CIN2+) were computed for the selected CADM1-m18/MAL-m1 marker panel using the thresholds as determined in the training set. The ROC curve was 
Discussion
Using a training/validation set approach we composed and analyzed a CADM1/MAL-specific methylation marker panel to be used for triage testing of hrHPV-positive women. When applying assay thresholds corresponding with 75.3% specificity (resulting in 68.4% sensitivity) or 52.5% specificity (resulting in 84.2% sensitivity), this panel was equally discriminatory for CIN3+ as cytology or the cytology/HPV16/18 genotyping combination in hrHPV-positive women.
Several previous studies already have indicated that methylation analysis of host cell genes in cervical scrapings holds great promise for detecting high-grade CIN lesions and cervical cancer (25, 26, (34) (35) (36) (37) . However, these studies were conducted on selected populations, such as outpatient referral populations or screening populations of women who were tested with cytology solely. This hampered comparison of methylation markers with cytology in a screening setting since cytology negative women had no follow-up. The strength of this study is the availability of cervical samples from prospective population-based screening studies conducted with hrHPV testing and with referral for colposcopy based on triage by cytology and/or hrHPV. This allowed comparison of the methylation markers with sole cytology or cytology/HPV16/18 genotyping for the triage of hrHPV-positive women.
However, a possible verification bias in favor of cytology cannot be excluded, since women were mainly referred on the basis of abnormal cytology (2) . Because loss to follow-up was most pronounced at the 18 month visit, the only moment at which women were referred on the basis of sole hrHPV testing (2), this could have resulted in a slight underestimation of the sensitivity of the methylation marker panel.
Another issue that deserves attention is that not only scrapes of women with CIN2 but also a small subset of women with CIN3 showed relatively low methylation levels. When for example the thresholds were applied that gave rise to a 81.6% CIN3+ sensitivity and at which all carcinomas and ACIS in the validation set were detected seven CIN3 lesions (m18), MAL-m1 (mal1), and MAL-m2 (mal2). Cluster 1 contains the following 7 marker panels: CADM1-m12/CADM1-m18/ MAL-m1/MAL-m2; CADM1-m12/CADM1-m18/MAL-m1; CADM1-m12/CADM1-m18/MAL-m2; CADM1-m18/MAL-m1/MAL-m2; CADM1-m12/CADM1-m18; CADM1-m18/MAL-m1; CADM1-m18/MAL-m2. For the single marker MAL-m2 no ROC curve could be generated since the MAL-m2 Ct ratios were 0 in more than 80% of the samples and therefore any Ct ratio threshold above 0 automatically results in a specificity >80%, which falls outside the specificity range of 20% to 80% used to generate the ROC curves. At a Ct ratio threshold of 0 the sensitivity value for MAL-m2 was 32.1% and the specificity 81.3%. Table 2 . Sensitivity, specificity, positive and negative predictive value for CIN3+ and referral percentage among hrHPV-positive women of the CADM1-m18/MAL-m1 marker panel at different cut-offs, cytology, and cytology combined with HPV16/18 positivity. 
